TY - JOUR
T1 - Prognostic significance of 99mTc Hynic-rh-annexin V scintigraphy during platinum-based chemotherapy in advanced lung cancer
AU - Kartachova, Marina
AU - Van Zandwijk, Nico
AU - Burgers, Sjaak
AU - Van Tinteren, Harm
AU - Verheij, Marcel
AU - Olmos, Renato Alfredo Valdés
PY - 2007/6/20
Y1 - 2007/6/20
N2 - Purpose: The purpose of this study was to evaluate if sequential 99mTmTc Hynic-rh- annexin V scintigraphy (TAS) can predict outcome in patients with advanced lung cancer, shortly after the start of platinum-based chemotherapy. Patients and Methods: In 16 consecutive chemotherapy-naive patients with advanced stage non-small-cell lung cancer scheduled for platinum-based chemotherapy, TAS was performed before and within 48 hours after the start of therapy. Chemotherapy-induced changes in tumor annexin V uptake, calculated as maximum count per pixel and expressed as percentage to baseline value, were compared with treatment response determined according to Response Evaluation Criteria in Solid Tumors. Results: A significant correlation (r 2 = 0.86; P = .0001) was found between annexin V metabolic changes and treatment outcome. All patients with notably increased annexin V tumor uptake showed complete or partial response. Less prominently increased or decreased uptake correlated with stable or progressive disease. Conclusion: TAS is a promising test to predict tumor response in patients with advanced lung cancer early in the course of platinum-based chemotherapy.
AB - Purpose: The purpose of this study was to evaluate if sequential 99mTmTc Hynic-rh- annexin V scintigraphy (TAS) can predict outcome in patients with advanced lung cancer, shortly after the start of platinum-based chemotherapy. Patients and Methods: In 16 consecutive chemotherapy-naive patients with advanced stage non-small-cell lung cancer scheduled for platinum-based chemotherapy, TAS was performed before and within 48 hours after the start of therapy. Chemotherapy-induced changes in tumor annexin V uptake, calculated as maximum count per pixel and expressed as percentage to baseline value, were compared with treatment response determined according to Response Evaluation Criteria in Solid Tumors. Results: A significant correlation (r 2 = 0.86; P = .0001) was found between annexin V metabolic changes and treatment outcome. All patients with notably increased annexin V tumor uptake showed complete or partial response. Less prominently increased or decreased uptake correlated with stable or progressive disease. Conclusion: TAS is a promising test to predict tumor response in patients with advanced lung cancer early in the course of platinum-based chemotherapy.
UR - http://www.scopus.com/inward/record.url?scp=34447253819&partnerID=8YFLogxK
U2 - 10.1200/JCO.2006.10.1337
DO - 10.1200/JCO.2006.10.1337
M3 - Article
C2 - 17577031
AN - SCOPUS:34447253819
SN - 0732-183X
VL - 25
SP - 2534
EP - 2539
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 18
ER -